Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06871111 · ClinicalTrials.gov registry record · Phase 1
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
A Phase 1 study of Cirrhosis, Liver and Liver Diseases, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06871111 is a Phase 1 study of Cirrhosis, Liver and Liver Diseases that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 24 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06871111, a Phase 1 study of Cirrhosis, Liver and Liver Diseases, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) trial is a single center prospective adaptive phase 1b clinical trial in patients who are hospitalized with complications of liver disease and have low fecal metabolite levels (butyrate and deoxycholic acid). The study intervention is 1 of 9 novel live Commensal Consortia each containing eight commensal bacterial strains derived from healthy donors. The primary objective of the study is to determine safety and tolerability of Commensal Consortia administration.
Conditions Studied
Interventions
- BIOLOGICAL Commensal Bacteria Strains
Study Locations (1)
Illinois
- The University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2028-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06871111
The ClinicalTrials.gov registry entry for NCT06871111 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (90% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 1 intervention - of which Commensal Bacteria Strains is the first listed.
NCT06871111 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06871111 about?
NCT06871111 is a clinical study titled "The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial". The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) trial is a single center prospective adaptive phase 1b clinical trial in patients who are hospitalized with complications of liver disease and have low fecal metabolite levels (butyrate and deoxycholic acid). The study interventi...
What is the current status of trial NCT06871111?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-08-04. Estimated completion is 2028-02-04.
What conditions does trial NCT06871111 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Liver Diseases, Liver Failure.
What interventions are being tested in trial NCT06871111?
The interventions under investigation include: Commensal Bacteria Strains (BIOLOGICAL).
Who is sponsoring clinical trial NCT06871111?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06871111 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
A Study of SIPLIZUMAB in AILD and LT Patients
RECRUITING · Phase 1
-
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
COMPLETED · Phase 1
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.